Earnings
Tarsus Shelves TP03 Filings In Europe And Japan, Citing Most-Favored-Nation Pricing Rules
The eye-care drugmaker also lifted its 2026 Xdemvy sales outlook to $715 million to $730 million after third-quarter sales of $194.6 million.
TARS
Tarsus Pharmaceuticals (TARS) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Tarsus Expensed $632.2 Million For Two Unapproved Retina Drugs, Leaving Equity At $104 Million
A $668.3 million quarterly loss hit the eye-drug maker's balance sheet, and its cash runway assumes no milestone payments come due.
Deals
Tarsus Books $632.2 Million Charge For Two Acquired Drugs, Swamping Record Xdemvy Sales
Xdemvy sales hit $194.6 million, but the third-quarter net loss reached $668.3 million after two pipeline deals.